OR WAIT null SECS
March 11, 2022
Video
Dr Jerry Bagel looks to the future of moderate-to-severe plaque psoriasis management.
March 04, 2022
Jerry Bagel, MD, MS, explains clinical trial data on the investigational anti-IL17A/F monoclonal antibody bimekizumab.
An overview of the novel selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib for the management of plaque psoriasis.
February 25, 2022
Dr Jerry Bagel describes the unmet needs of plaque psoriasis management.